文献速递中毒与环境急症消化、代谢与肾脏急症

停用阿片类处方、阿片治疗时长与过量或自杀死亡的关系:美国退伍军人中的观察性评价

Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation.
PubMed 文献 · BMJ · 2020-03-04
一句话结论在退伍军人中,停用阿片类治疗与过量或自杀死亡风险升高相关,且治疗时间越长,停药后风险越高(>400天者HR 6.77)。

该观察性评价纳入美国退伍军人健康管理局2013至2014财年有阿片类镇痛药门诊处方的1 394 102例患者,用多变量Cox非比例风险回归模型分析停药、治疗时长与过量或自杀死亡的关系。共发生2887例过量或自杀死亡。停药与死亡风险升高相关,且随治疗时长增加而升高:≤30天HR 1.67、31-90天HR 2.80、91-400天HR 3.95、>400天HR 6.77。描述性生命表数据提示,开始或停止阿片治疗之后过量或自杀死亡率立即升高,约3至12个月内下降。作者认为,观察到的关联不能假定为因果,处方开始和停止的背景可能影响风险且未被研究。

要点

  • 停用阿片类治疗与过量或自杀死亡风险升高相关,且治疗时间越长风险越高:≤30天HR 1.67、31-90天HR 2.80、91-400天HR 3.95、>400天HR 6.77。
  • 描述性生命表数据提示,开始或停止阿片治疗后过量或自杀死亡率立即升高,约3至12个月内下降。
  • 停药 incidence 总体为57.4%(n=799 668),按治疗时长≤30天为32.0%、31-90天8.7%、91-400天22.7%、>400天36.6%。
  • 作者认为,观察到的关联不能假定为因果;处方开始和停止的背景可能影响风险且未被研究。

适用人群与场景

  • 美国退伍军人健康管理局2013财年至2014财年末(2012年10月1日至2014年9月30日)有阿片类镇痛药门诊处方的患者,共1 394 102例。

研究设计与关键结果

  • 观察性评价,纳入1 394 102例有阿片类镇痛药门诊处方的退伍军人健康管理局患者,共发生2887例过量或自杀死亡。
  • 停药 incidence 总体为57.4%(n=799 668),按治疗时长≤30天为32.0%、31-90天8.7%、91-400天22.7%、>400天36.6%。
  • 停药与治疗时长的交互作用显著(P<0.001);停药与过量或自杀死亡风险升高相关,且治疗时间越长风险越高:HR 1.67(≤30天)、2.80(31-90天)、3.95(91-400天)、6.77(>400天)。
  • 描述性生命表数据提示,开始或停止阿片治疗后过量或自杀死亡率立即升高,约3至12个月内下降。

证据类型、等级与局限

  • 证据类型:观察性评价。
  • 作者指出,观察到的关联不能假定为因果;处方开始和停止的背景可能影响风险且未被研究。

对床旁实践的改变

  • 作者认为,减轻开始和停止阿片治疗期间风险的策略目前不是长期阿片使用指南的重点。
  • 作者认为,更安全的阿片处方应从患者角度出发,关注使患者在开始和停止阿片治疗后处于过量或自杀风险的因素,尤其是前三个月。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To examine the associations between stopping treatment with opioids, length of treatment, and death from overdose or suicide in the Veterans Health Administration.

DESIGN: Observational evaluation.

SETTING: Veterans Health Administration.

PARTICIPANTS: 1 394 102 patients in the Veterans Health Administration with an outpatient prescription for an opioid analgesic from fiscal year 2013 to the end of fiscal year 2014 (1 October 2012 to 30 September 2014).

MAIN OUTCOME MEASURES: A multivariable Cox non-proportional hazards regression model examined death from overdose or suicide, with the interaction of time varying opioid cessation by length of treatment (≤30, 31-90, 91-400, and >400 days) as the main covariates. Stopping treatment with opioids was measured as the time when a patient was estimated to have no prescription for opioids, up to the end of the next fiscal year (2014) or the patient's death.

RESULTS: 2887 deaths from overdose or suicide were found. The incidence of stopping opioid treatment was 57.4% (n=799 668) overall, and based on length of opioid treatment was 32.0% (≤30 days), 8.7% (31-90 days), 22.7% (91-400 days), and 36.6% (>400 days). The interaction between stopping treatment with opioids and length of treatment was significant (P<0.001); stopping treatment was associated with an increased risk of death from overdose or suicide regardless of the length of treatment, with the risk increasing the longer patients were treated. Hazard ratios for patients who stopped opioid treatment (with reference values for all other covariates) were 1.67 (≤30 days), 2.80 (31-90 days), 3.95 (91-400 days), and 6.77 (>400 days). Descriptive life table data suggested that death rates for overdose or suicide increased immediately after starting or stopping treatment with opioids, with the incidence decreasing over about three to 12 months.

CONCLUSIONS: Patients were at greater risk of death from overdose or suicide after stopping opioid treatment, with an increase in the risk the longer patients had been treated before stopping. Descriptive data suggested that starting treatment with opioids was also a risk period. Strategies to mitigate the risk in these periods are not currently a focus of guidelines for long term use of opioids. The associations observed cannot be assumed to be causal; the context in which opioid prescriptions were started and stopped might contribute to risk and was not investigated. Safer prescribing of opioids should take a broader view on patient safety and mitigate the risk from the patient's perspective. Factors to address are those that place patients at risk for overdose or suicide after beginning and stopping opioid treatment, especially in the first three months.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Oliva EM, Bowe T, Manhapra A, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ. 2020. PMID: 32131996. doi:10.1136/bmj.m283

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。